$ADT

ADT Inc. Stock 12‑Month Price Target Cut to $8.13, Implies 26% Upside

ADT Inc.'s average stock price target was reduced from $8.23 to $8.13 by analysts, with a range of $7 to $9. This implies a 26% upside from the Oct. 12 closing price. The consensus rating remains 'Hold' among 8 analysts, with 2 'Buys', 5 'Holds', and 1 'Sell'.

Original reporting
Published Oct 13, 2026, 10:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ADT Inc. Stock 12‑Month Price Target Cut to $8.13, Implies 26% Upside — source image
Decision brief

The 30-second read

$ADTBearishMed
01

Why it matters

The downgrade lowers the perceived upside, likely prompting short‑term selling pressure.

02

Market read

Analyst target cuts are a direct catalyst for price movement; traders may adjust positions accordingly.

03

What to watch

Potential upcoming contract wins or cost‑saving initiatives not reflected in the target revision.

Relevance 5/10Novelty 5/10Timing: pre‑market today

Background

The article reports a recent analyst consensus price‑target reduction for ADT Inc., a U.S. security‑services company.

Company-level read

Ticker impact

$ADTBearishHigh confidence
Context

Analyst consensus price target for ADT was lowered from $8.23 to $8.13, indicating a fresh downgrade.

Expected impact

likely downward pressure as investors price in the lower target

Evidence & confidence

Analyst price‑target revisions are a direct catalyst; the cut is new information and implies a 26% upside is now less credible.

Market effects

Security services sector may see modest re‑rating as analysts adjust expectations for peers.

U.S. market may see slight pullback in related security‑service stocks.

Limited to U.S. equities; no broader macro effect.

Counterpoint

Some investors may view the cut as an over‑reaction and see buying opportunity if fundamentals remain solid.

Key entities

  • ADT Inc.

    U.S. listed security services provider.

Related articles

$ADTMedAI 8/10

Consumer Discretionary - Specialized Consumer Services Stocks Q2 Results: Benchmarking ADT (NYSE:ADT)

H&R Block (HRB) reported Q2 revenue of $1.14B, up 3% YoY, beating estimates and raising guidance. Its stock rose 11.9%. Matthews (MATW) reported a 29.6% YoY revenue decline, missing estimates, and its stock fell 20%. Pool (POOL) met revenue expectations but missed EPS estimates, with its stock unchanged. Carriage Services (CSV) reported flat revenue, missing estimates, and its stock dropped 16.8%.

$ADTMed

ADT Reports Second Quarter 2026 Results

ADT Inc. (ADT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADT Reports Second Quarter 2026 Results Continued strong cash generation GAAP Operating Cash Flows up 18%, Adjusted Free Cash Flow (including swaps) up 48% Returned $684 million to shareholders through share repurchases and dividends in first half of the year Raising

$CLYMHighAI 8/10

Climb Bio reports early data on budoprutug for kidney diseases

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.